AC Immune reported progress in its neurodegenerative disease pipeline with key clinical trial milestones expected in H2 2026, including Phase 2 results for its Parkinson’s drug ACI-7104 and Phase 1 data for its NLRP3 inhibitor. The company triggered a $12 million milestone payment from Takeda after starting a new cohort in its Alzheimer’s ACI-24 trial. With CHF 75.4 million in cash, AC Immune is financially positioned to fund operations into late 2027, supported by partnerships with major pharma firms like Lilly and Takeda. These developments highlight AC Immune’s growing focus on wholly-owned programs and its strong collaboration model.
XRP price rose to $1.43, up 3.13% in 24 hours, with strong trading volume of $3.41 billion. Analysts highlight an inverse head-and-shoulders pattern forming, targeting a breakout above $1.55 that could trigger a 35% rally toward $2. Large holders hav...
Oracle's capital spending on AI infrastructure has surged, causing free cash flow to turn sharply negative and shifting funding reliance from internal cash to debt. This shift raises the cost of capital and pressures investment returns, evidenced by ...
Injective's Meridian mainnet upgrade proposal (IIP-701) passed with 99% support from INJ stakers, marking a major step for institutional adoption. The upgrade, scheduled for September 24, 2026, introduces regulated token standards on Injective's EVM,...
President Trump will host Chinese President Xi Jinping at the White House to discuss key issues including trade, tariffs, Taiwan, AI, and rare-earth exports. The talks come amid concerns that failure to extend a rare-earth export ban truce could esca...
Ethereum has regained the $2,500 price level amid a significant 28% drop in ETH held on exchanges since May 2025, reducing the liquid supply available for trading. Increased staking, now at over 35%, further removes ETH from circulation, tightening s...
